Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo Nordisk between ...

Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...